Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,428.00
Bid: 12,432.00
Ask: 12,436.00
Change: -82.00 (-0.66%)
Spread: 4.00 (0.032%)
Open: 12,556.00
High: 12,562.00
Low: 12,420.00
Prev. Close: 12,510.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Leaked letters show AstraZeneca vaccine commitment not as Thailand claimed

Mon, 19th Jul 2021 15:07

By Panu Wongcha-um

BANGKOK, July 19 (Reuters) - AstraZeneca Plc has
told Thailand it should be able to supply around 6 million doses
of its COVID-19 vaccine per month, leaked correspondence showed,
contradicting assertions by Thai officials that the government
had been promised 10 million.

Thailand's push for 10 million monthly doses comes as it
considers imposing vaccine export curbs on Thai-manufactured
vaccine to shore up domestic supplies, a move that could create
problems for its neighbours, some of which are battling similar
or more severe coronavirus crises.

But a June 25 letter by AstraZeneca to Thailand's health
minister showed that the Anglo-Swedish drugmaker had offered to
supply just 5-6 million doses a month to Thailand from a local
plant, or one third of the amount produced by its partner Siam
Bioscience, which is owned by Thailand's king.

"I hope you will be pleased that this is nearly twice the
volume we discussed during our meeting," AstraZeneca's vice
president of global corporate affairs, Sjoerd Hubben, said in
the letter, referring to a September 2020 meeting with Thai
officials.

At that meeting, the government officials estimated Thailand
required around 3 million doses per month, Hubben wrote.

The correspondence was first reported by Isara news agency
and later seen by Reuters.

AstraZeneca also explained at the September meeting that
Thailand had an opportunity to procure more via the
international COVAX vaccine-sharing scheme, Hubben said in the
letter.

Thailand, which never made supply deals with COVAX, instead
decided in January to buy 26 million doses from AstraZeneca and
another 35 million doses in May, the letter showed.

The director-General of the Thai Disease Control Department,
Opas Karnkawinpong, confirmed on Sunday that the letter was
authentic. He told reporters the 3 million figure had been a
rough estimate and Thailand had formally asked AstraZeneca in
April 2021 to provide 10 million monthly doses.

He did not say whether AstraZeneca had agreed to that, and
said it was understood that vaccine availability depended on
output and volume might need to be agreed on a monthly basis.

AstraZeneca had no comment on Monday on the leaked letter.

The letter also detailed AstraZeneca's supply commitments of
nearly 114 million doses elsewhere in Asia - a supply chain that
has become uncertain due to potential export restrictions by the
Thai government.

It planned to supply 50 million doses to Indonesia, 30
million to Vietnam, 16.5 million to the Philippines, 10 million
to Taiwan and 6.4 million to Malaysia, the letter showed.

Opposition lawmaker Wiroj Lakkhanaadisorn said Thai
authorities were prepared for neither a global supply shortage
nor the severe impact of variants of concern.

"The government was over-confident about the situation when
making these plans," he told Reuters on Monday. "They have been
very slow and careless."

Thailand has inoculated just 5.2% of its population so far.

A source with knowledge of Thailand's AstraZeneca agreement
said 61 million doses, or about a third of the local factory's
agreed output, would be delivered to Thailand overall, but no
monthly volume commitment had ever been agreed.
(Writing by Martin Petty
Editing by Mark Heinrich)

More News
9 Feb 2024 07:51

LONDON BRIEFING: Barclays buys Tesco's retail banking business

(Alliance News) - Stocks in London are called to open higher on Friday, closing off a busy corporate week.

Read more
8 Feb 2024 17:00

LONDON MARKET CLOSE: Softer earnings weigh on underperforming FTSE 100

(Alliance News) - London's FTSE 100 ended lower on Thursday, with mixed corporate updates keeping a lid on enthusiasm, while in New York the S&P 500 has the 5,000 point mark in touching distance.

Read more
8 Feb 2024 14:42

London close: Stocks slip as US jobless claims fall

(Sharecast News) - London markets experienced a downturn in trading on Thursday, with stocks relinquishing earlier gains as investors processed a decrease in jobless claims in the United States.

Read more
8 Feb 2024 12:08

LONDON MARKET MIDDAY: DS Smith surges on takeover approach from Mondi

(Alliance News) - Stock prices in London were mixed at midday Thursday, as markets struggled to find direction amid a mixed wave of corporate updates and earnings.

Read more
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.